Pressmeddelande

BioStock: DexTech takes a new approach to myeloma treatment

Cision Publicerad: 09 Jun 2022 08:34

Uppsala-based DexTech are now preparing for the proof-of-concept study that will evaluate the drug candidate OsteoDex for the treatment of multiple myeloma. The candidate has shown clear clinical efficacy results in castration-resistant prostate cancer and preclinical indications of efficacy also in multiple myeloma. BioStock took closer look at the multiple myeloma treatment market to identify the potential of DexTech's complementary venture.

Read the full article about DexTech's cadidate on biostock.se:

https://www.biostock.se/en/2022/06/dextech-takes-a-new-approach-to-myeloma-treatment/

This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se

Nyheter om DexTech Medical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!